We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold on to Bruker (BRKR) Stock for Now
Read MoreHide Full Article
Bruker Corporation (BRKR - Free Report) is well poised for growth in the coming quarters, backed by a slew of product launches. A solid performance in the fourth quarter of 2020 and potential in the BSI Nano Group also buoy optimism. However, foreign-exchange fluctuations and persistent pandemic-led business challenges are major downsides.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 85.9% compared with the 68.1% growth of the industry and 56.2% rise of the S&P 500.
The renowned provider of life science and materials research systems and associated products has a market capitalization of $10.23 billion. The company projects 6.7% growth for the next five years and expects to witness continued improvements in its business. Bruker surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed the same in one, the average surprise being 78.17%.
Let’s delve deeper.
Product Launches: We are upbeat about the slew of product launches by Bruker over the past few months. The company, in March, launched the Fourier 80 system, which is a next-generation, high-performance 80 MHz Fourier Transform Nuclear Magnetic Resonance benchtop spectrometer for multinuclear gradient spectroscopy, with industry-standard automation options in the United States and Canada. In January, Bruker announced receipt of the FDA’s clearance and the subsequent U.S. launch of the MBT Sepsityper Kit US IVD for rapid microbial identification of various microorganisms from positive blood cultures on the MALDI Biotyper CA System.
In December 2020, the company launched the CE-IVD-labelled FluoroType SARS-CoV-2/Flu/RSV winter four-plex polymerase chain reaction panel in Europe.
Potential in BSI Nano Group: We are upbeat about the segment’s performance over the past few months. In fourth-quarter 2020, revenues for NANO's microelectronics and semiconductor metrology products grew in double digits due to strength in semiconductor markets. Bruker, during the quarter, initiated additional restructuring and cost actions within the Nano group to improve the fundamental cost structure while investing in Nano's spatial biology and targeted multi-omics strategy.
The company anticipates high single-digit organic revenue growth at Nano groups in 2021. Overall, the Nano Group holds strong long-term potential on higher demand from industrial markets, semiconductors and growing academic markets.
Strong Q4 Results: Bruker’s better-than-expected results in fourth-quarter 2020 buoy optimism. Additional customer acceptance of the 1.2 GHz NMR system during the quarter bodes well. Strength in Bruker’s BSI Life Science and robust performances in Europe and Asia Pacific buoy optimism. Expansion of gross margin is encouraging as well. The company’s 2021 financial guidance with strong growth expectations over 2020 is also encouraging.
Downsides
Exposure to Currency Movement: We are concerned about Bruker’s exposure to currency fluctuations as it rakes in a significant portion of its sales from international markets. As a result, currency fluctuations continue to result in foreign currency transaction losses for the company. In addition, currency fluctuations could cause the price of Bruker’s products to be less competitive than its principal competitors' offerings.
Coronavirus Dampeners: Bruker’s 2020 results reflected decline in both reported and organic revenues, primarily due to COVID-19-related disruptions. BioSpin group’s revenues registered significant decline due to COVID-related customer disruptions and installation delays, mostly in the first half of 2020. Segmental performance was dismal, primarily due to pandemic-led business disruptions.
Estimate Trend
Bruker has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings per share has moved 3.5% north to $1.77.
The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $508.8 million, suggesting a 20% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Hologic, Inc. (HOLX - Free Report) , Hill-Rom Holdings, Inc. and DENTSPLY SIRONA Inc. (XRAY - Free Report) .
Hill-Rom’s long-term earnings growth rate is estimated at 7.3%. It currently carries a Zacks Rank #2.
DENTSPLY’s long-term earnings growth rate is estimated at 20%. The company presently carries a Zacks Rank #2.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Here's Why You Should Hold on to Bruker (BRKR) Stock for Now
Bruker Corporation (BRKR - Free Report) is well poised for growth in the coming quarters, backed by a slew of product launches. A solid performance in the fourth quarter of 2020 and potential in the BSI Nano Group also buoy optimism. However, foreign-exchange fluctuations and persistent pandemic-led business challenges are major downsides.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 85.9% compared with the 68.1% growth of the industry and 56.2% rise of the S&P 500.
The renowned provider of life science and materials research systems and associated products has a market capitalization of $10.23 billion. The company projects 6.7% growth for the next five years and expects to witness continued improvements in its business. Bruker surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed the same in one, the average surprise being 78.17%.
Let’s delve deeper.
Product Launches: We are upbeat about the slew of product launches by Bruker over the past few months. The company, in March, launched the Fourier 80 system, which is a next-generation, high-performance 80 MHz Fourier Transform Nuclear Magnetic Resonance benchtop spectrometer for multinuclear gradient spectroscopy, with industry-standard automation options in the United States and Canada. In January, Bruker announced receipt of the FDA’s clearance and the subsequent U.S. launch of the MBT Sepsityper Kit US IVD for rapid microbial identification of various microorganisms from positive blood cultures on the MALDI Biotyper CA System.
In December 2020, the company launched the CE-IVD-labelled FluoroType SARS-CoV-2/Flu/RSV winter four-plex polymerase chain reaction panel in Europe.
Potential in BSI Nano Group: We are upbeat about the segment’s performance over the past few months. In fourth-quarter 2020, revenues for NANO's microelectronics and semiconductor metrology products grew in double digits due to strength in semiconductor markets. Bruker, during the quarter, initiated additional restructuring and cost actions within the Nano group to improve the fundamental cost structure while investing in Nano's spatial biology and targeted multi-omics strategy.
The company anticipates high single-digit organic revenue growth at Nano groups in 2021. Overall, the Nano Group holds strong long-term potential on higher demand from industrial markets, semiconductors and growing academic markets.
Strong Q4 Results: Bruker’s better-than-expected results in fourth-quarter 2020 buoy optimism. Additional customer acceptance of the 1.2 GHz NMR system during the quarter bodes well. Strength in Bruker’s BSI Life Science and robust performances in Europe and Asia Pacific buoy optimism. Expansion of gross margin is encouraging as well. The company’s 2021 financial guidance with strong growth expectations over 2020 is also encouraging.
Downsides
Exposure to Currency Movement: We are concerned about Bruker’s exposure to currency fluctuations as it rakes in a significant portion of its sales from international markets. As a result, currency fluctuations continue to result in foreign currency transaction losses for the company. In addition, currency fluctuations could cause the price of Bruker’s products to be less competitive than its principal competitors' offerings.
Coronavirus Dampeners: Bruker’s 2020 results reflected decline in both reported and organic revenues, primarily due to COVID-19-related disruptions. BioSpin group’s revenues registered significant decline due to COVID-related customer disruptions and installation delays, mostly in the first half of 2020. Segmental performance was dismal, primarily due to pandemic-led business disruptions.
Estimate Trend
Bruker has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings per share has moved 3.5% north to $1.77.
The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $508.8 million, suggesting a 20% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Hologic, Inc. (HOLX - Free Report) , Hill-Rom Holdings, Inc. and DENTSPLY SIRONA Inc. (XRAY - Free Report) .
Hologic’s long-term earnings growth rate is estimated at 15.4%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hill-Rom’s long-term earnings growth rate is estimated at 7.3%. It currently carries a Zacks Rank #2.
DENTSPLY’s long-term earnings growth rate is estimated at 20%. The company presently carries a Zacks Rank #2.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2021 today >>